Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals (NASDAQ: JAZZ) has initiated a global Phase 2b clinical trial for suvecaltamide (JZP385), targeting adults with moderate to severe essential tremor (ET). The trial, featuring a double-blind, placebo-controlled design, will enroll 400 participants across 50 sites in the U.S., U.K., and EU. Patients will receive doses of suvecaltamide or placebo for 12 weeks, with efficacy measured by the Tremor Research Group Essential Tremor Rating Assessment Scale. Results are expected in the first half of 2024, marking a critical step in addressing a long-standing unmet need for ET therapies.
PharmaMar and Jazz Pharmaceuticals have initiated a confirmatory Phase 3 trial, named LAGOON, for Zepzelca (lurbinectedin) to treat relapsed small cell lung cancer (SCLC). The trial, which will enroll 705 patients across over 100 sites mainly in North America and Europe, aims to demonstrate overall survival and progression-free survival outcomes. If successful, LAGOON could support full regulatory approval in the U.S. and marketing authorization in Europe. Zepzelca, previously approved under accelerated conditions, is seen as a critical treatment option for SCLC patients.
Jazz Pharmaceuticals announced initial positive results from a Phase 2/3 trial of Rylaze™ (asparaginase erwinia chrysanthemi) for adults and children with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase. Conducted with the Children's Oncology Group, the trial evaluated different dosing schedules, showing a favorable safety profile and clinically meaningful serum asparaginase activity levels. Initial results will guide regulatory filings, including a supplemental Biologics Licensing Application for a new dosing schedule in early 2022.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the presentation of six studies on Epidiolex (cannabidiol) at the upcoming 2021 American Epilepsy Society meeting from December 3-7 in Chicago, IL. This marks the first presentation following the integration of GW Pharmaceuticals. Key findings from a U.S.-based caregiver survey indicate improvements in emotional functioning, cognition, and a reduction in seizure frequency for patients with Lennox-Gastaut and Dravet syndromes. The company aims to enhance its neuroscience R&D portfolio to treat additional neurological conditions.
Jazz Pharmaceuticals (Nasdaq: JAZZ) recently announced the enrollment of the first patient in the IMforte Phase 3 trial, evaluating Zepzelca® (lurbinectedin) with Tecentriq® (atezolizumab) for extensive-stage small cell lung cancer (ES-SCLC). This trial aims to assess the combination's efficacy in improving progression-free and overall survival compared to Tecentriq alone. If successful, it could support an FDA application for Zepzelca as a first-line maintenance therapy. This collaboration with Roche addresses a significant medical need, given the aggressive nature of ES-SCLC.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in two upcoming virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 16, 2021, scheduled for 11:20 – 11:55 a.m. ET. The second is the Evercore ISI HealthCONx Conference on November 30, 2021, from 2:40 – 3:25 p.m. ET. Webcasts of the presentations can be accessed on their website, with replays available for 30 days. Jazz is a biopharmaceutical company based in Dublin, focusing on innovative treatments in neuroscience and oncology.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported a 39% increase in total revenues to $838.1 million for Q3 2021 compared to Q3 2020. Recently launched or acquired products contributed over 50% to net sales. Key highlights include strong adoption of Xywav, resulting in $153.1 million in sales, and a 21% revenue growth for Epidiolex at $160.4 million. The company raised its 2021 earnings guidance and decreased its net leverage ratio to 4.4x. However, GAAP net income showed a loss of $52.8 million per diluted share, contrasting with a profit of $148.2 million in the previous year.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present 16 new data abstracts at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include findings on Rylaze for acute lymphoblastic leukemia and Vyxeos for acute myeloid leukemia. The data showcases Jazz's commitment to improving treatments for rare blood cancers through collaborations and innovative trials. CEO Robert Iannone emphasizes the importance of these studies for developing new treatment options for patients.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will release its 2021 Q3 financial results on November 9, 2021, after U.S. market close. A live audio webcast is scheduled for 4:30 p.m. ET, with a replay available until November 16, 2021. The company is dedicated to innovating treatments for serious diseases, focusing on neuroscience and oncology. Interested parties can access the webcast through the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced a webcast scheduled for October 13, 2021 at 4:30 p.m. ET to update investors on Xywav, the FDA-approved treatment for idiopathic hypersomnia (IH) in adults, which received approval on August 12, 2021. Senior management will discuss commercial launch plans, alongside insights from sleep expert Dr. Richard Bogan. The webcast will be accessible via Jazz’s website, with a replay available for one week.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
